COX-2 and CD105 expression in breast cancer and disease-free survival;Expressão da COX-2 e CD105 no câncer de mama e sobrevida livre de doença

Revista da Associacao Medica Brasileira

Volumn 52, Issue 4, 2006, Pages 275-280

  Grudzinski, Melina ^a,b   Cambruzzi, Eduardo ^a   Lahude, Eduardo ^a   Savaris, Ricardo Francalacci ^a   Pedrini, José Luiz ^a   Zettler, Cláudio Galleano ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b NONE   (Brazil)

Author keywords

Breast cancer; CD105; Cyclooxygenase 2

Indexed keywords

EID: 33748538693     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302006000400031     Document Type: Article

References (28)

1. Brasil.Ministério da Saúde. Estimativas da incidência e mortalidade por câncer no Brasil. Instituto Nacional do Câncer - INCA 2003. Available from: http://www.inca.gov.br/conteudo_view.asp?id=336
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
3. Gradishar WJ. The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 2005;89(Suppl 1):S17-S26.
4. Vainio H, Morgan G. Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. BMJ 1998;317:828.
5. Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 2003;119:374-80.
6. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.
7. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999;106:37S-42S.
8. Hussain T, Gupta S, Mukhtar H, Smith WL, DeWitt DL, Garavito RM. Cyclooxygenase-2 and prostate carcinogenesis cyclooxygenases: structural, cellular, and molecular biology. Cancer Lett 2003;191:125-35.
9. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 2002;299:886-90.
10. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
11. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
12. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
13. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-57.
14. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-34.
15. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651-6.
16. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-92.
17. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000;92:486-92.
18. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004;35:176-83.
19. Dales JP, Garcia S, Andrac L, Carpentier S, Ramuz O, Lavaut MN, et al. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 2004;24:1197-204.
20. Recht AC, Troyan SL, Sadowsky NL. Local-regional recurrence after mastectomy or breast-conserving therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Disease of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.p.731-4.
21. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours (UICC). 6th ed. New York: Wiley-Liss; 2002.
22. World Health Organization. Pathology and genetics of tumours of the breast and female genital organs. Oxford: Oxford University Press; 2003.
23. Browner WS, Newman TB, Cummings SR, Hulley SB. Estimando o tamanho de amostra e o poder estatístico: pontos básicos. In: Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB, editors. Delineando a pesquisa clínica, uma abordagem epidemiológica. 2nd ed. Porto Alegre: Artmed; 2003. p.83-104.
24. O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1034-40.
25. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGFR2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 2004;90:1216-21.
26. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.
27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
28. Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997;65:22-7.